Tagged with B

S.M.B. Laboratories Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing company. Consequently, I joined SMB Laboratories in 1978 as a result of identifying certain commercial opportunities, as is the case…

Baker & McKenzie Belgium Today, B&M differentiates itself by what it calls its ‘fluency’ in the way you think, work and behave which enables you to navigate the legal complexities across practices and boarders with ease and allows you to bring the very best of your global expertise to your clients. Has this model…

ThromboGenics Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud of? At the moment, ThromboGenics basically has one key product, Ocriplasmin, which has recently completed phase-III clinical studies. Initially, this…

Cegedim Belgium October marks the completion of your first full year as general manager of Cegedim’s Belgian affiliate. To what extent do you feel that the skills you’ve acquired in your career at Therabel and B Braun – both pharmaceutical and medical devices companies, apply to Cegedim? What were some of main…

Cegedim Belgium October marks the completion of your first full year as general manager of Cegedim’s Belgian affiliate. To what extent do you feel that the skills you’ve acquired in your career at Therabel and B Braun – both pharmaceutical and medical devices companies, apply to Cegedim? What were some of main…

Baker & McKenzie Belgium Today, B&M differentiates itself by what it calls its ‘fluency’ in the way you think, work and behave which enables you to navigate the legal complexities across practices and boarders with ease and allows you to bring the very best of your global expertise to your clients. Has this model…

BeCRO What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior to establishing BeCRO, several of our members were already participants of other associations that also included pharmaceutical companies and academia,…

Array   An in-depth viewpoint on the current taxation situation for pharmaceutical companies operating in Belgium today, looking at incentive programs and relative positioning in Europe. Mr Eynatten, can you please provide our readers with an overview of the value added services that Deloitte offers to the life sciences industry in…

Array   Donald Niesten and Omer Saka discuss the current dynamics of the healthcare and pharmaceutical sectors in Belgium, the challenges of entering the market and the issue of effective communication with stakeholders, as well as offering opinions on the merits of ‘clusterization’.  Deloitte is certainly renowned for its strong network…

Lonza - Belgium Mr Pasini, before becoming site director of the Verviers plant you were acting as the Head of Investor Relations for Lonza. Can you provide us with an overview of your background and outline to what extent your previous role helped to prepare you to become Site Director of the Verviers…

Phebra Australia Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of relatively specialized pharmaceutical products. Over the years we saw a growing demand for these special, difficult to manufacture drugs or…

BioSingapore In addition to being the director of strategic planning at Quintiles you are also the Chairman of BioSingapore. In this context, can you please introduce BioSingapore and describe its main objectives? BioSingapore was created in 2004 by the Singapore Economic Development Board (EDB) to create an interactive platform for the…